Evidence map›Paper›PMID 37593580›Full record

ArticleRSC medicinal chemistry2023

Design, synthesis and evaluation of halogenated phenazine antibacterial prodrugs targeting nitroreductase enzymes for activation.

Ke Liu, Tao Xiao, Hongfen Yang, Manyun Chen, Qiwen Gao, Beau R Brummel, Yousong Ding, Robert W Huigens

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ke LiuDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida Gainesville Florida 32610 USA rhuigens@cop.ufl.edu.ORCID https://orcid.org/0000-0001-6827-6706
Tao XiaoDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida Gainesville Florida 32610 USA rhuigens@cop.ufl.edu.
Hongfen YangDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida Gainesville Florida 32610 USA rhuigens@cop.ufl.edu.
Manyun ChenDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida Gainesville Florida 32610 USA rhuigens@cop.ufl.edu.
Qiwen GaoDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida Gainesville Florida 32610 USA rhuigens@cop.ufl.edu.
Beau R BrummelDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida Gainesville Florida 32610 USA rhuigens@cop.ufl.edu.
Yousong DingDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida Gainesville Florida 32610 USA rhuigens@cop.ufl.edu.ORCID https://orcid.org/0000-0001-8610-0659
Robert W HuigensDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida Gainesville Florida 32610 USA rhuigens@cop.ufl.edu.ORCID https://orcid.org/0000-0003-3811-2721
University of Florida · US

Funding

Comprehensive Training Program in Oral BiologyT90DE021990 · NIDCR · UNIVERSITY OF FLORIDA · PI Jose A Lemos · 2011 to 2026
$8.2M
NIH Equipment Supplement to R35GM128742R35GM128742 · NIGMS · UNIVERSITY OF FLORIDA · PI Yousong Ding · 2018 to 2026
$3.4M
Indole Alkaloids and Phenazine Antibiotics: New Platforms for Drug DiscoveryR35GM128621 · NIGMS · UNIVERSITY OF FLORIDA · PI HUIGENS, ROBERT WILLIAM · 2018 to 2022
$1.7M
Acquisition of a Q Exactive HF Hybrid Quadrupole-OrbitrapS10OD021758 · OD · UNIVERSITY OF FLORIDA · PI BASSO, KARI B · 2017 to 2017
$600k
NIDCR NIH HHS T90 DE021990NIGMS NIH HHS R35 GM128621NIGMS NIH HHS R35 GM128742NIH HHS S10 OD021758
6 · The paper itself

Abstract

It is of great importance to develop new strategies to combat antibiotic resistance. Our lab has discovered halogenated phenazine (HP) analogues that are highly active against multidrug-resistant bacterial pathogens. Here, we report the design, synthesis, and study of a new series of nitroarene-based HP prodrugs that leverage intracellular nitroreductase (NTR) enzymes for activation and subsequent release of active HP agents. Our goals of developing HP prodrugs are to (1) mitigate off-target metal chelation (potential toxicity), (2) possess motifs to facilitate intracellular, bacterial-specific HP release, (3) improve water solubility, and (4) prevent undesirable metabolism (

Identifiers

PMID37593580
PMCPMC10429720
OpenAlexW4379512289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.